Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Syros Pharmaceuticals appoints Jason Haas CFO » 08:03
10/12/21
10/12
08:03
10/12/21
08:03
SYRS

Syros Pharmaceuticals

$4.47 /

-0.03 (-0.67%)

Syros Pharmaceuticals…

Syros Pharmaceuticals announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25 years of healthcare investment banking and corporate finance experience to Syros. "We are pleased to welcome Jason to Syros, who brings an exceptional depth of financial, strategic, and leadership experience in the life sciences space," said Nancy Simonian, M.D., Chief Executive Officer of Syros. "Jason has a proven track record as a strategic advisor to biotechnology and pharmaceutical companies across all stages of development. He joins Syros at a pivotal time, as we advance towards becoming a commercial-stage company, with a growing portfolio in targeted hematology and selective CDK inhibition."

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$4.47 /

-0.03 (-0.67%)

SYRS Syros Pharmaceuticals
$4.47 /

-0.03 (-0.67%)

09/27/21 Roth Capital
Veteran Chee coming aboard a positive for Syros, says Roth Capital
09/23/21 Roth Capital
Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital
05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
SYRS Syros Pharmaceuticals
$4.47 /

-0.03 (-0.67%)

  • 20
    Jan
Conference/Events
Syros Pharmaceuticals management to meet virtually with Piper Sandler » 04:55
10/01/21
10/01
04:55
10/01/21
04:55
SYRS

Syros Pharmaceuticals

$4.46 /

+0.15 (+3.48%)

Virtual Meeting to be…

Virtual Meeting to be held on October 1 hosted by Piper Sandler.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$4.46 /

+0.15 (+3.48%)

SYRS Syros Pharmaceuticals
$4.46 /

+0.15 (+3.48%)

09/27/21 Roth Capital
Veteran Chee coming aboard a positive for Syros, says Roth Capital
09/23/21 Roth Capital
Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital
05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
SYRS Syros Pharmaceuticals
$4.46 /

+0.15 (+3.48%)

  • 20
    Jan
Hot Stocks
Syros reports 1st patient in dose confirmation study of ATO oral for APL » 08:16
09/29/21
09/29
08:16
09/29/21
08:16
SYRS

Syros Pharmaceuticals

$4.51 /

-0.31 (-6.43%)

Syros Pharmaceuticals…

Syros Pharmaceuticals announced that the first patient has been dosed in the dose confirmation study of SY-2101, a novel oral form of arsenic trioxide, ATO. The trial will evaluate the pharmacokinetics , safety, and tolerability of SY-2101 to confirm the optimal dose to advance into a planned Phase 3 clinical trial in newly diagnosed acute promyelocytic leukemia patients. "The current standard of care cures most patients but is tremendously burdensome, requiring regular and lengthy infusions of an IV formulation of ATO over nearly a yearlong course of treatment," said Farhad Ravandi, M.D., Professor of Medicine, Chief of Section of Acute Myeloid Leukemia, Department of Leukemia at The University of Texas - MD Anderson Cancer Center. "An oral form of ATO that offers similar efficacy while dramatically reducing the treatment burden would represent a major advance for APL patients. The preliminary Phase 1 data for SY-2101 are very promising, and I look forward to its continued advancement in the current and future studies." "We are thrilled to now be dosing patients in our dose confirmation study of SY-2101," said David A. Roth, M.D., Chief Medical Officer at Syros. "This milestone represents an important step toward delivering a new option for people with APL and a meaningful advance in our efforts to build a leading portfolio of targeted hematology therapies. We believe SY-2101 could quickly become the new standard of care for APL by offering patients similar efficacy with a substantially more accessible and convenient therapy. We plan to move swiftly from our dose confirmation study into a Phase 3 trial next year, with the goal of filing a New Drug Application, NDA, in 2024." ...Syros expects to report data from this study in the first half of 2022. Based on the results of the dose confirmation study, Syros expects to initiate a Phase 3 clinical trial in newly diagnosed APL patients. Based on input from the FDA, Syros believes molecular complete response rate and event-free survival in comparison to historical control data with IV ATO may support accelerated and full approval, respectively.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$4.51 /

-0.31 (-6.43%)

SYRS Syros Pharmaceuticals
$4.51 /

-0.31 (-6.43%)

09/27/21 Roth Capital
Veteran Chee coming aboard a positive for Syros, says Roth Capital
09/23/21 Roth Capital
Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital
05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
SYRS Syros Pharmaceuticals
$4.51 /

-0.31 (-6.43%)

  • 20
    Jan
Conference/Events
Syros Pharmaceuticals management to meet virtually with Piper Sandler » 13:39
09/28/21
09/28
13:39
09/28/21
13:39
SYRS

Syros Pharmaceuticals

$4.54 /

-0.28 (-5.81%)

Virtual Meeting to be…

Virtual Meeting to be held on October 1 hosted by Piper Sandler.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$4.54 /

-0.28 (-5.81%)

SYRS Syros Pharmaceuticals
$4.54 /

-0.28 (-5.81%)

09/27/21 Roth Capital
Veteran Chee coming aboard a positive for Syros, says Roth Capital
09/23/21 Roth Capital
Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital
05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
SYRS Syros Pharmaceuticals
$4.54 /

-0.28 (-5.81%)

  • 20
    Jan
Recommendations
Veteran Chee coming aboard a positive for Syros, says Roth Capital » 13:46
09/27/21
09/27
13:46
09/27/21
13:46
SYRS

Syros Pharmaceuticals

$4.81 /

+0.05 (+1.05%)

After Syros…

After Syros Pharmaceuticals announced earlier its appointment of Conley Chee as the company's first Chief Commercial Officer, Roth Capital analyst Zegbeh Jallah said a large pharma veteran with such "deep commercial expertise" coming onboard provides "further validation of the value of Syros' advancing clinical pipeline." As the stock continues to be under pressure, the validation of Chee's appointment is a positive, argues Jallah, who has a Buy rating and $23 price target on Syros shares.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$4.81 /

+0.05 (+1.05%)

SYRS Syros Pharmaceuticals
$4.81 /

+0.05 (+1.05%)

09/23/21 Roth Capital
Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital
05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
11/10/20 Brookline
Syros Pharmaceuticals initiated with a Buy at Brookline
SYRS Syros Pharmaceuticals
$4.81 /

+0.05 (+1.05%)

  • 20
    Jan
Hot Stocks
Syros Pharmaceuticals appointment of Conley Chee as Chief Commercial Officer » 08:05
09/27/21
09/27
08:05
09/27/21
08:05
SYRS

Syros Pharmaceuticals

$4.76 /

+0.06 (+1.28%)

Syros Pharmaceuticals …

Syros Pharmaceuticals announced the appointment of Conley Chee as the company's first Chief Commercial Officer. Mr. Chee brings 20 years of pharmaceutical sales leadership, marketing and strategy experience in the U.S. and globally, with particular expertise in driving commercial strategy for novel medicines for the treatment of cancer. "We are pleased to welcome Conley to Syros. With multiple programs progressing through late-stage development and towards potential new drug applications in 2024, now is the right time to begin building our commercial organization," said Nancy Simonian, M.D., Chief Executive Officer of Syros. "Conley brings a wealth of relevant experience in oncology commercial leadership, including a track record of building effective commercial organizations and successfully launching new targeted therapies. We look forward to his many contributions as we mature Syros into a fully integrated biopharmaceutical company and work to deliver our medicines to patients in need." "Syros' growing portfolio of later-stage targeted investigational medicines has the potential to offer new standards of care to people with hematologic malignancies who need and deserve better treatment options," said Mr. Chee. "I look forward to working with the leadership team to develop a commercial strategy that maximizes synergies across Syros' portfolio to bring products to market and profoundly impact the lives of patients."

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$4.76 /

+0.06 (+1.28%)

SYRS Syros Pharmaceuticals
$4.76 /

+0.06 (+1.28%)

09/23/21 Roth Capital
Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital
05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
11/10/20 Brookline
Syros Pharmaceuticals initiated with a Buy at Brookline
SYRS Syros Pharmaceuticals
$4.76 /

+0.06 (+1.28%)

  • 20
    Jan
Over a month ago
Recommendations
Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital » 08:28
09/23/21
09/23
08:28
09/23/21
08:28
SYRS

Syros Pharmaceuticals

$4.42 /

-0.315 (-6.65%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah raised the firm's price target on Syros Pharmaceuticals to $23 from $20 and keeps a Buy rating on the shares after updated Phase 1 dose-escalation data for SY-5609 in heavily-pretreated patients with solid tumors was presented at ESMO. Notably, 38% of patients achieved SD and tumor reductions up to 20%, which was "encouraging" since most had progressed on prior therapies, the analyst contends. Jallah also highlights that SY-5609 was best tolerated on a 7-day-on/7-day-off regimen, and Syros plans to use this regimen with chemo in Pancreatic Cancer, and with a BTK inhibitor in Mantle Cell Lymphoma.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$4.42 /

-0.315 (-6.65%)

SYRS Syros Pharmaceuticals
$4.42 /

-0.315 (-6.65%)

05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
11/10/20 Brookline
Syros Pharmaceuticals initiated with a Buy at Brookline
11/05/20 Roth Capital
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital
SYRS Syros Pharmaceuticals
$4.42 /

-0.315 (-6.65%)

  • 20
    Jan
Conference/Events
Syros Pharmaceuticals to host conference call » 15:55
09/20/21
09/20
15:55
09/20/21
15:55
SYRS

Syros Pharmaceuticals

$4.98 /

-0.09 (-1.78%)

Management discusses the…

Management discusses the new clinical and pre-clinical data for SY-5609, as presented at the recent ESMO Congress 2021, on a conference call to be held on September 20 at 4 pm. Webcast Link

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$4.98 /

-0.09 (-1.78%)

SYRS Syros Pharmaceuticals
$4.98 /

-0.09 (-1.78%)

05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
11/10/20 Brookline
Syros Pharmaceuticals initiated with a Buy at Brookline
11/05/20 Roth Capital
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital
SYRS Syros Pharmaceuticals
$4.98 /

-0.09 (-1.78%)

  • 20
    Jan
Hot Stocks
Syros Pharmaceuticals presents new data from Phase 1 trial of SY-5609 » 11:32
09/20/21
09/20
11:32
09/20/21
11:32
SYRS

Syros Pharmaceuticals

$5.14 /

+0.07 (+1.38%)

Syros Pharmaceuticals…

Syros Pharmaceuticals announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 inhibitor, demonstrating clinical activity at tolerable doses as a single agent across multiple tumor types. The data is being presented in an oral presentation at the 2021 ESMO Congress. The Phase 1 multi-center, open-label dose-escalation study of SY-5609 enrolled patients with advanced breast, colorectal, lung, ovarian and pancreatic cancers, as well as patients with solid tumors of any histology harboring Rb pathway alterations. Patients were treated in cohorts exploring continuous daily dosing as well as intermittent dosing regimens, including seven days on treatment and seven days off and five days on treatment and two days off. As of July 6, 54 patients treated with single-agent SY-5609 in the study were eligible for a safety analysis and 45 patients were evaluable for clinical response. The median age of patients enrolled in the study was 65.5. Patients had been heavily pre-treated with as many as eight prior therapies and a median of four prior therapies. Across all doses and schedules, the majority of adverse events were low-grade and reversible. The most common treatment-emergent AEs were nausea, diarrhea, thrombocytopenia, fatigue and anemia. Low rate of discontinuations due to AEs. Tolerability was optimized with 7d on/7d off schedule, which had lowest rates of treatment-emergent AEs, while demonstrating comparable rates of stable disease as seen with more dose-intense regimens, supporting the selection of this schedule for further development of SY-5609. The maximum tolerated dose of the 7d on/7d off schedule has not yet been reached. Changes in POLR2A mRNA expression, a pharmacodynamic marker for CDK7 inhibition, were associated with anti-tumor activity and were sustained for at least three days following drug cessation, supporting intermittent dosing. Thirteen patients achieved SD, with tumor regressions of up to 20% in six of those patients, across multiple tumor types. The most substantial clinical activity was observed in heavily pre-treated patients with advanced pancreatic cancer. Five of 13 evaluable patients achieved SD, with tumor reductions in two of those patients. Reductions in the CA 19-9 tumor marker, which is used in clinical practice to monitor tumor progression, were observed in three of four pancreatic cancer patients with serial CA 19-9 data. These reductions ranged from 32% to 72%. Notably, one metastatic pancreatic cancer patient who had failed two prior lines of therapy and relapsed after a third line of treatment experienced prolonged SD of up to 10 months. Analysis of clinical activity by tumor type and mutational status supports the mechanistic rationale for SY-5609 in Rb-altered and KRAS-mutant cancers. Further development of SY-5609 will explore three combination regimens, focusing initially on indications with compelling clinical and/or preclinical activity, as well as a strong mechanistic rationale and high unmet need. Syros plans to initiate an expansion cohort evaluating SY-5609 in combination with chemotherapy for the treatment of pancreatic cancer in the fourth quarter of 2021. Syros also plans to initiate a Phase 1b trial evaluating SY-5609 in combination with a Bruton's tyrosine kinase inhibitor for the treatment of mantle cell lymphoma in the first half of 2022. Syros plans to employ a 7d on/7d off dosing schedule in both of these trials. In addition, as announced in August 2021, Syros entered into an agreement with Roche to explore SY-5609 in combination with atezolizumab in patients with BRAF-mutant colorectal cancer in Roche's ongoing Phase 1/1b INTRINSIC trial. Syros also presented new preclinical data at ESMO evaluating the anti-tumor and PD activity of intermittent dosing regimens for SY-5609, as well as new preclinical data evaluating SY-5609 as a single agent and in combination with chemotherapy in pancreatic cancer models. Taken together, these data further support Syros' dose expansion strategy, including the decision to use a 7d on/7d off dosing schedule and combine with chemotherapy in patients with pancreatic cancer. The data showed that SY-5609: Induced robust anti-tumor activity as a single agent in ovarian cancer models that was maintained at higher doses on intermittent schedules, including a 7d on/7d off schedule. POLR2A PD effects were sustained in tumor tissue through 72 hours post-dosing, consistent with what was observed in patients in the dose-escalation study. Induced regressions as a single agent in half of the pancreatic cancer models that were studied, including models derived from heavily pre-treated patients. Resulted in deeper responses when combined on 7d on/7d off schedule with gemcitabine in KRAS-mutant pancreatic models than either agent alone.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$5.14 /

+0.07 (+1.38%)

SYRS Syros Pharmaceuticals
$5.14 /

+0.07 (+1.38%)

05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
11/10/20 Brookline
Syros Pharmaceuticals initiated with a Buy at Brookline
11/05/20 Roth Capital
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital
SYRS Syros Pharmaceuticals
$5.14 /

+0.07 (+1.38%)

  • 20
    Jan
Conference/Events
Syros Pharmaceuticals to host conference call » 04:55
09/20/21
09/20
04:55
09/20/21
04:55
SYRS

Syros Pharmaceuticals

$5.06 /

-0.38 (-6.99%)

Management discusses the…

Management discusses the new clinical and pre-clinical data for SY-5609, as presented at the recent ESMO Congress 2021, on a conference call to be held on September 20 at 4 pm. Webcast Link

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$5.06 /

-0.38 (-6.99%)

SYRS Syros Pharmaceuticals
$5.06 /

-0.38 (-6.99%)

05/06/21 Piper Sandler
Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler
03/05/21 Alliance Global Partners
Syros price target lowered to $14 from $18 at Alliance Global Partners
11/10/20 Brookline
Syros Pharmaceuticals initiated with a Buy at Brookline
11/05/20 Roth Capital
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital
SYRS Syros Pharmaceuticals
$5.06 /

-0.38 (-6.99%)

  • 20
    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.